He et al. found that the gut microbial metabolite butyrate stimulates the IL-12 signaling pathway to promote CD8+ T cell-mediated anti-tumor response, leading to improved efficacy of the oxaliplatin therapy. This evidence concerns the gene CD8A and neoplasm.